Login
Companies $KURA
$7.15 +$0.06 (0.85%) After hours
Kura Oncology, Inc. logo

Kura Oncology, Inc.

kuraoncology.com

What Do They Do?

Sells KOMZIFTI, an oral medicine for adults with a specific form of leukemia, and develops small-molecule treatments for cancer and other diseases.

How Do They Make Money?

Most revenue comes from collaboration arrangements: partners pay for licensed rights and related work through upfront fees, milestone payments, cost reimbursements and royalties on product sales. In the United States, specialty distributors and pharmacies pay for KOMZIFTI when it is delivered.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright
3.2%
Collaboration Revenue
97%

Who Are Their Customers?

In the United States, specialty distributors and specialty pharmacies buy KOMZIFTI directly, then resell it to pharmacies, health care providers and patients.

Do Revenues Turn Into Profits?

No. It lost $278.7M in FY2025.

Operating income, FY2025
−450% of revenue
▼ −57% (Loss) vs FY2024 (−$193.2M, −359%)
Net income, FY2025
−413% of revenue
▼ −60% (Loss) vs FY2024 (−$174M, −323%)
Free cash flow, FY2025
−105% of revenue
▼ Turned to a loss vs FY2024 ($133.8M, 248%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +10%
vs $20.8M in Q3 FY2025
Net income
▲ +5% (Loss)
vs −$74.1M in Q3 FY2025
Collaboration Revenue share of revenue vs 100.0% in Q3 FY2025
  • Nov 10, 2026 Jennifer Fulk joined as chief financial officer
  • Sep 9, 2026 Kura transferred next-generation menin inhibitor rights to Caspian Kura contributed rights to menin inhibitors for diabetes and cardiometabolic diseases; Caspian will handle their development and commercialization.

Commercial launch The earlier report described clinical product candidates and trials; the latest describes an approved KOMZIFTI and U.S. commercial sales, moving Kura from development into selling a medicine.

Commercial rights The earlier report said Kura held global commercial rights to its programs; the latest says Kura and Kyowa Kirin share U.S. commercialization, while Kyowa Kirin handles sales outside the United States.

Additional disease areas The earlier pipeline focused on cancer; the latest also describes next-generation menin inhibitors being explored for diabetes and cardiometabolic disorders.

Revenue over time
Product revenue, net Collaboration Revenue
$100M$50M$0

Who Do They Compete With?

Competes with Syndax, Janssen, Dainippon Sumitomo, Servier, Biomea Fusion, CHARM Therapeutics, Abbvie, Genentech, Novartis, Astellas, BMS, Rigel, Daiichi-Sankyo, Merck, AstraZeneca, Exelixis, Eisai, Amgen, and Mirati

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support